These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

889 related articles for article (PubMed ID: 31469627)

  • 1. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
    Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
    Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
    J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.
    Schoenenberger-Arnaiz JA; Ahmad-Diaz F; Miralbes-Torner M; Aragones-Eroles A; Cano-Marron M; Palomar-Martinez M
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e30-e35. PubMed ID: 32296502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M; Buurma V; Shah M; Fahim G
    Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study.
    Areskog Lejbman I; Torisson G; Resman F; Sjövall F
    Acta Anaesthesiol Scand; 2024 Apr; 68(4):530-537. PubMed ID: 38407447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
    Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
    Cojutti PG; Morandin E; Baraldo M; Pea F
    Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy.
    Bue M; Sou T; Okkels ASL; Hanberg P; Thorsted A; Friberg LE; Andersson TL; Öbrink-Hansen K; Christensen S
    Int J Infect Dis; 2020 Mar; 92():133-140. PubMed ID: 31978581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
    Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM
    Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF).
    Donnellan S; Wright DFB; Roberts JA; Duffull SB; Schollum JBW; Putt TL; Wallis SC; Walker RJ
    Eur J Clin Pharmacol; 2020 Feb; 76(2):239-247. PubMed ID: 31814045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
    Chua NG; Loo L; Hee DKH; Lim TP; Ng TM; Hoo GSR; Soong JL; Ong JCL; Tang SSL; Zhou YP; Lee W; Lee LS; Cove M; Ling LM; Kwa AL
    J Crit Care; 2022 Apr; 68():107-113. PubMed ID: 34999376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study.
    Dhaese SAM; Thooft ADJ; Farkas A; Lipman J; Verstraete AG; Stove V; Roberts JA; De Waele JJ
    J Crit Care; 2019 Aug; 52():75-79. PubMed ID: 30986758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
    Benech N; Dumitrescu O; Conrad A; Balsat M; Paubelle E; Ducastelle-Lepretre S; Labussière-Wallet H; Salles G; Cohen S; Goutelle S; Ader F;
    J Antimicrob Chemother; 2019 Sep; 74(9):2676-2680. PubMed ID: 31219562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.